Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis

British Medical Journal

Volumn 325, Issue 7374, 2002, Pages 1202-1206

  Wald, David S ^a   Law, Malcolm ^b   Morris, Joan K ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MALE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

EID: 0037164375     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.325.7374.1202     Document Type: Article

References (16)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
2. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease. Systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-92.
3. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiological evidence. Ann Intern Med 1999;131:363-75.
4. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. J Am Coll Cardiol 2000;86:1005-9.
5. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998;316:894-8.
6. Wald DS, Bishop L, Wald NJ, Law MR, Hennessy E, McPartlin J, et al. Randomised trial of folic acid supplementation on serum homocysteine levels. Arch Intern Med 2001;161:695-700.
7. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1997;37:1-31.
8. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation 1998;98:2520-6.
9. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GH, Heil SG, Bruschke AV, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997;96:2573-7.
10. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ. The methylenetetrahydrogolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 2000:153:161-8.
11. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
12. Law MR, Wald NJ. Risk factor thresholds: Their existence under scrutiny. BMJ 2002;324:1570-6.
13. Brattstrom L, Wilcken DEL. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 2000:72:315-23.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
15. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
16. Kluijtmans LAJ, Boers GHD, Kraus JP, van den Henvel LPWJ, Cruysberg JRM, Trijbels FJM, et al. The molecular basis of cystathionine β-synthase deficiency in Dutch patients with homocystinuria: Effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Gen 1999;65:59-67.